China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

NCT07809178 | Not Yet Recruiting DMC

• 1 other identifier: HX-B-2025024
• Study Type: observational
• Target: 608
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?

Conditions

Unruptured Intracranial Aneurysms; Pituitary Neuroendocrine Tumor; Craniopharyngioma; Meningioma; Germinoma; Rathke Cleft Cysts; Chordoma; Optic Pathway Glioma; Hypothalamic Neoplasms

Keywords

Tumor in sellar region; Unruptured intracranial aneurysms

Outcome Measures

Primary Outcomes (2)

• Aneurysm progression

  The diameter of aneurysm neck, the diameter of aneurysm dome, the volume of aneurysm, aneurysm rupture status

  From enrollment to the end of treatment at 24 months

• Tumor related complication and progression

  The related complication and progression of tumor in sellar region: pituitary hormone level, visual acuity and visual field, hydrocephalus and tumor recurrence.

  From enrollment to the end of treatment at 24 months

Study Arms (3)

Priority to Tumor

Tumor resection followed by aneurysm treatment

Procedure: Tumor resection followed by aneurysm treatment

Priority to Aneurysm

Aneurysm treatment followed by tumor resection

Procedure: Aneurysm treatment followed by tumor resection

Only Tumor

Tumor resection without aneurysm treatment but observation

Other: Observation

Interventions

Tumor resection followed by aneurysm treatment PROCEDURE

Tumor resection followed by aneurysm treatment

Priority to Tumor

Aneurysm treatment followed by tumor resection PROCEDURE

Aneurysm treatment followed by tumor resection

Priority to Aneurysm

Observation OTHER

Tumor resection without aneurysm treatment but observation

Only Tumor

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed of tumor in sellar region with unruptured intracranial aneurysms in the Chinese population

You may qualify if:

• Preoperative enhanced head MRI showing a suspected diagnosis of a sella region lesion, and preoperative head CTA/DSA confirming an unruptured intracranial aneurysm.
• Patients with primary sella region tumor and unruptured intracranial aneurysms that have not previously accepted surgical treatment.
• Patients with tumor in sellar region requiring craniotomy or endoscopic transnasal surgery and/or an aneurysm requiring craniotomy, endovascular treatment, or observation only.
• The patients are in good general health, without severe underlying medical conditions, and capable of tolerating surgical treatment.
• Patients or their legal guardians have signed an informed consent form and voluntarily agreed to participate in the clinical trial.

You may not qualify if:

• Patients with recurrent sella region tumors.
• Patients with previously treated intracranial aneurysm.
• Pregnant or breastfeeding women.
• Any other condition that, in the investigator's judgment, makes the patient unsuitable for trial participation.

Sponsors & Collaborators

• Cheng sen: lead
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: collaborator
• West China Hospital: collaborator
• Xijing Hospital: collaborator
• Shandong Provincial Hospital: collaborator
• The First Affiliated Hospital of Anhui Medical University: collaborator
• First Affiliated Hospital of Chongqing Medical University: collaborator
• Shengjing Hospital: collaborator
• Lanzhou University Second Hospital: collaborator
• The First Hospital of Jilin University: collaborator
• People's Hospital of Xinjiang Uygur Autonomous Region: collaborator
• Guangdong Provincial Hospital of Traditional Chinese Medicine: collaborator
• Huashan Hospital: collaborator
• Jinling Hospital, China: collaborator

Study Sites (1)

Beijing Tiantan Hospital affiliated to Capital Medical University

Beijing, China, 100070, China

Location

Related Publications (5)

• Almeida Silva JM, Campos RR, Souza RR, Sette Dos Santos ME, Aguiar GB. Spontaneous subarachnoid haemorrhage from rupture of an anterior communicating artery aneurysm in a patient with pituitary macroadenoma. Neurocirugia (Astur). 2014 Mar-Apr;25(2):81-5. doi: 10.1016/j.neucir.2013.03.005. Epub 2013 Jul 9.

  PMID: 23845268 RESULT

• Schwab KE, Gailloud P, Wyse G, Tamargo RJ. Limitations of magnetic resonance imaging and magnetic resonance angiography in the diagnosis of intracranial aneurysms. Neurosurgery. 2008 Jul;63(1):29-34; discussion 34-5. doi: 10.1227/01.NEU.0000335068.53190.46.

  PMID: 18728566 RESULT

• Oshino S, Nishino A, Suzuki T, Arita H, Tateishi A, Matsumoto K, Shimokawa T, Kinoshita M, Yoshimine T, Saitoh Y. Prevalence of cerebral aneurysm in patients with acromegaly. Pituitary. 2013 Jun;16(2):195-201. doi: 10.1007/s11102-012-0404-x.

  PMID: 22752346 RESULT

• de Sena Barbosa MG, Otavio da Silva V, Santos Ferreira LH, de Souza RLV, Pipek LZ, de Oliveira Almeida G, Figueiredo EG, Rabelo NN, Chaurasia B. Intracranial aneurysm coexisting with pituitary adenoma: a systematic review. Ann Med Surg (Lond). 2024 Oct 25;86(12):7232-7237. doi: 10.1097/MS9.0000000000002692. eCollection 2024 Dec.

  PMID: 39649870 RESULT

• Cai K, Jia Y, Jin L, Qiao N, Xiao Y, Wu W, Ru S, Liu F, Liu C, Cao L, Gui S. Adult craniopharyngioma concomitant with unruptured intracranial aneurysms: incidence, risk factors, and treatment strategies. J Neurosurg. 2024 Jun 14;141(6):1712-1722. doi: 10.3171/2024.3.JNS232258. Print 2024 Dec 1.

  PMID: 38875730 RESULT

MeSH Terms

Conditions

Craniopharyngioma; Meningioma; Germinoma; Central Nervous System Cysts; Chordoma; Hypothalamic Neoplasms

Interventions

Observation

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Nervous System Diseases; Nervous System Malformations; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Supratentorial Neoplasms; Brain Neoplasms; Brain Diseases; Central Nervous System Diseases; Hypothalamic Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Central Study Contacts

Sen Cheng, MD

CONTACT

+8615313520109; dr.sencheng@hotmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 17, 2026
• First Posted: September 9, 2026
• Study Start: September 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 1, 2031
• Last Updated: September 9, 2026

Record last verified: 2026-09

Locations

CN (1)